#USA #PTC Therapeutics #Warren #Sephience #ST-920

Overview of PTC Therapeutics’ Third Quarter 2026

PTC Therapeutics, Inc. (NASDAQ: PTCT) has released its financial results for the third quarter of 2026, highlighting robust growth metrics that showcase the company’s solid product performance. The total revenue for Q3 reached an impressive $358 million, emphasizing a strong trajectory with product revenue alone amounting to $276 million. This remarkable increase is largely attributed to the successful launch and increasing market penetration of their leading product, Sephience (sepiapterin).

Product Growth and Revenue Details

In Q3 2026, Sephience generated $182 million in revenue, indicating consistent growth in the US market along with ongoing international expansion efforts. The breakdown of Sephience revenue shows $145 million from US sales and $37 million internationally, reflecting an over 20% growth from the previous quarter. As of September 30, 2026, the company boasts over 2,000 active patients receiving treatment worldwide, showcasing the product's wide acceptance and the significant potential of expanding its reach.

Furthermore, PTC Therapeutics has raised its full-year 2026 revenue guidance to between $1.29 billion and $1.32 billion, with product revenue expectations now set between $960 million and $990 million. This optimistic outlook reinforces the company’s strategic position in the biopharmaceutical landscape.

Innovative Acquisitions and Future Prospects

In exciting corporate news, PTC Therapeutics acquired ST-920, a gene therapy for Fabry disease, for an upfront cost of $111 million, further underlining its commitment to expand its innovative treatment portfolio. This therapy is anticipated to receive its Biologics License Application (BLA) submission in Q4 2026. The company is hopeful for potential FDA accelerated approval and a market launch for ST-920 by 2027.

Additionally, advancements are palpable within the Huntington's disease program with Votoplam. A critical Type C meeting with the FDA is expected in Q1 2027, where discussions will revolve around Phase 2 findings and pathways for expedited approval. Furthermore, research substantiating the effectiveness of the Vatiquinone compound for Friedreich's ataxia began this quarter, with a global study set to include about 120 patients aged 7 to 21.

Financial Highlights

The third quarter financial highlights solidify PTC’s position:

• - Total net product and royalty revenue soared to $357.6 million, a stark increase from $201.7 million in Q3 2025.
• - Net product revenue across its commercial portfolio rose to $275.9 million, reflecting more than a 100% growth in comparison to the same quarter last year.
• - The company reported a net loss of $51.7 million for Q3 2026, a notable swing from the previous year's net income of $15.9 million, primarily due to acquired research and development costs related to new assets.

Despite the net loss, PTC ended the quarter with $2.13 billion in cash and cash equivalents, which bolsters its ability to invest in ongoing R&D and marketing endeavors.

Conclusion

PTC Therapeutics is on a promising path, marked by significant revenue growth, strategic acquisitions, and innovative development pipelines. The company remains dedicated to delivering transformative therapies to patients with rare diseases. Investors and stakeholders are excited to see how these developments will shape the future of PTC as it continues to rise as a competitive entity within the biopharmaceutical industry. For more information, you can visit their website or check their social media channels for the latest updates on their groundbreaking work and financial strategies.